110 related articles for article (PubMed ID: 1695049)
1. [Effectiveness of cisplatin alone and in combination within the scope of primary therapy of ovarian cancer. Results of a prospective multicenter study].
Richter P; Krafft W; Müller U; Brückmann D; Homann S; König EM; Lotze P; Morack G; Neubert S; Nöschel H
Zentralbl Gynakol; 1990; 112(7):421-9. PubMed ID: 1695049
[TBL] [Abstract][Full Text] [Related]
2. [The effectiveness of platinum in mono- anc combination therapy in a prospective multicenter study].
Krafft W
Zentralbl Gynakol; 1989; 111(14):938-46. PubMed ID: 2678834
[TBL] [Abstract][Full Text] [Related]
3. Chemotherapy in advanced ovarian carcinoma: current standards of care based on randomized trials.
Thigpen T; Vance R; Puneky L; Khansur T
Gynecol Oncol; 1994 Dec; 55(3 Pt 2):S97-107. PubMed ID: 7835816
[TBL] [Abstract][Full Text] [Related]
4. Randomized trial of initial therapy with melphalan versus cisplatin-based combination chemotherapy in patients with advanced ovarian carcinoma: initial and long term results--Eastern Cooperative Oncology Group Study E2878.
Wadler S; Yeap B; Vogl S; Carbone P
Cancer; 1996 Feb; 77(4):733-42. PubMed ID: 8616766
[TBL] [Abstract][Full Text] [Related]
5. [Drug therapy of ovarian carcinoma].
Dittrich C
Wien Med Wochenschr; 1996; 146(1-2):23-34. PubMed ID: 8835492
[TBL] [Abstract][Full Text] [Related]
6. ICON 2 and ICON 3 data in previously untreated ovarian cancer: results to date.
Harper P
Semin Oncol; 1997 Oct; 24(5 Suppl 15):S15-23-S15-25. PubMed ID: 9346217
[TBL] [Abstract][Full Text] [Related]
7. Medical therapy of advanced malignant epithelial tumours of the ovary.
Colombo N; Parma G; Bocciolone L; Franchi D; Sideri M; Maggioni A
Forum (Genova); 2000; 10(4):323-32. PubMed ID: 11535983
[TBL] [Abstract][Full Text] [Related]
8. Cisplatin-MECY (methotrexate-leucovorin rescue plus cyclophosphamide) versus cisplatin-CHAD (cyclophosphamide, hexamethylmelamine, doxorubicin, and cisplatin) as initial chemotherapy in stage III-IV ovarian adenocarcinoma.
Barlow JJ; Lele SB
Cancer Treat Rep; 1984 Dec; 68(12):1433-8. PubMed ID: 6439408
[TBL] [Abstract][Full Text] [Related]
9. Phase II trial of intraperitoneal cisplatin with intravenous doxorubicin and cyclophosphamide in previously untreated patients with advanced ovarian cancer-long-term follow-up.
Morgan RJ; Braly P; Cecchi G; Leong L; Shibata S; Margolin K; Somlo G; McNamara M; Longmate J; Schinke S; Raschko J; Nagasawa S; Kogut N; Parker P; Stein A; Cho J; Smith E; Coluzzi P; Najera L; Johnson D; Womack E; Doroshow JH
Gynecol Oncol; 1999 Dec; 75(3):419-26. PubMed ID: 10600300
[TBL] [Abstract][Full Text] [Related]
10. Carboplatin versus cisplatin in ovarian cancer.
Alberts DS
Semin Oncol; 1995 Oct; 22(5 Suppl 12):88-90. PubMed ID: 7481869
[TBL] [Abstract][Full Text] [Related]
11. Cyclophosphamide and cisplatin versus paclitaxel and cisplatin: a phase III randomized trial in patients with suboptimal stage III/IV ovarian cancer (from the Gynecologic Oncology Group).
McGuire WP; Hoskins WJ; Brady MF; Kucera PR; Partridge EE; Look KY; Clarke-Pearson DL; Davidson M
Semin Oncol; 1996 Oct; 23(5 Suppl 12):40-7. PubMed ID: 8941409
[TBL] [Abstract][Full Text] [Related]
12. [Studies of second-look operations (SLO) in ovarian cancer].
Yuzawa H
Gan To Kagaku Ryoho; 1989 Apr; 16(4 Pt 2-2):1310-6. PubMed ID: 2658822
[TBL] [Abstract][Full Text] [Related]
13. [Combined modality for recurrent and disseminated ovarian cancer--CAPF combination chemotherapy and second-look operation].
Inagaki J; Ogawa M; Horikoshi N; Ezaki K; Inoue K; Aiba K; Komyo M; Miyamoto H; Ikeda K; Kubo H
Gan No Rinsho; 1983 Aug; 29(10):1291-5. PubMed ID: 6685195
[TBL] [Abstract][Full Text] [Related]
14. [Importance of platinum dose intensity in treatment of epithelial ovarian cancer. Austrian Study Group for Therapy of Ovarian Cancer].
Sevelda P; Kurz C; Obermair A; Vavra N; Breitenecker G; Czerwenka K; Dittrich C; Salzer H
Wien Klin Wochenschr; 1993; 105(24):732-6. PubMed ID: 8116312
[TBL] [Abstract][Full Text] [Related]
15. [Effect of 2 different forms of chemotherapy on remission in patients with advanced ovarian cancer].
Krommer K; Keller G; Csaba I; Garadnay B; Göcze P
Zentralbl Gynakol; 1990; 112(17):1105-10. PubMed ID: 2264421
[TBL] [Abstract][Full Text] [Related]
16. [Combination chemotherapy of ovarian cancer with cisplatinum, aclarubicin and tegafur].
Wada Y; Suzuki M; Shinagawa S; Saito Y; Nishiya I; Maki M; Yajima A; Hiroi M; Sato A
Gan To Kagaku Ryoho; 1989 Aug; 16(8 Pt 1):2589-94. PubMed ID: 2505683
[TBL] [Abstract][Full Text] [Related]
17. Using the expected survival to explain differences between the results of randomized trials: a case in advanced ovarian cancer.
Buyse M; Burzykowski T; Parmar M; Torri V; Omura G; Colombo N; Williams C; Conte P; Vermorken J; ;
J Clin Oncol; 2003 May; 21(9):1682-7. PubMed ID: 12721242
[TBL] [Abstract][Full Text] [Related]
18. [Latest information in the diagnoses of ovarian carcinoma].
Isonishi S
Gan To Kagaku Ryoho; 2002 Aug; 29(8):1351-7. PubMed ID: 12214460
[TBL] [Abstract][Full Text] [Related]
19. [Prognostic factors of common epithelial ovarian cancer treated by surgery and cisplatin based combination chemotherapy].
Sasaki H; Ochiai K; Terashima Y; Mochizuki S; Soda T; Nishimura H; Yakushiji M; Hirabayashi M
Gan No Rinsho; 1989 Oct; 35(13):1615-20. PubMed ID: 2585733
[TBL] [Abstract][Full Text] [Related]
20. [Toxicity and efficacy of chemotherapy dependent on circadian time of cytostatic drug administration].
Zuchowska-Vogelgesang B; Pernal J; Zemełka T
Przegl Lek; 1996; 53(12):870-3. PubMed ID: 9163011
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
